Efficacy and tolerability of folate-aminopterin therapy in a rat focal model of multiple sclerosis

J Neuroinflammation. 2021 Jan 20;18(1):30. doi: 10.1186/s12974-021-02073-7.

Abstract

Background: Activated macrophages in the experimental model of multiple sclerosis (MS) express folate receptor-β (FR-β), representing a promising target for the treatment of MS. Here, we both evaluated the efficacy of a novel folate-aminopterin construct (EC2319) in a rat focal model of multiple sclerosis (MS) and investigated the utility of 68Ga-labeled 1,4,7-triazacyclononane-1,4,7-triacetic acid-conjugated folate (68Ga-FOL) for assessing inflammatory lesions. In addition, we investigated whether FR-β is expressed in the brain of patients with MS.

Methods: Focal delayed-type hypersensitivity experimental autoimmune encephalomyelitis (fDTH-EAE) was induced in 40 Lewis rats; 20 healthy Lewis rats were used as controls. Rats were divided into six groups according to the duration of disease (control, acute, or chronic) and intervention (vehicle versus EC2319). 68Ga-FOL analyses, histology, and immunofluorescence of the brain were performed to evaluate the efficacy of subcutaneously administered EC2319 on lesion development. Immunofluorescence was used to assess FR-β expression in postmortem brain samples from 5 patients with MS and 5 healthy controls.

Results: Immunofluorescence and histological analyses revealed significant reductions in FR-β expression (P < 0.05) and lesion size (P < 0.01), as well as improved inducible nitric oxide synthase/mannose receptor C type 1 ratios (P < 0.01) in macrophages and microglia during the chronic but not acute phase of fDTH-EAE in EC2319-treated rats. The uptake of IV-injected 68Ga-FOL in the brain was low and did not differ between the groups, but the in vitro binding of 68Ga-FOL was significantly lower in EC2319-treated rats (P < 0.01). FR-β positivity was observed in chronically active lesions and in normal-appearing white matter in MS brain samples.

Conclusions: EC2319 was well tolerated and attenuated inflammation and lesion development in a rat model of a chronic progressive form of MS. Human MS patients have FR-β-positive cells in chronically active plaques, which suggests that these results may have translational relevance.

Keywords: Aminopterin; Experimental autoimmune encephalomyelitis; Folate receptor; Inflammation; Macrophages; Multiple sclerosis; Positron emission tomography.

MeSH terms

  • Aminopterin / pharmacology*
  • Animals
  • Encephalomyelitis, Autoimmune, Experimental / pathology*
  • Folate Receptor 2 / metabolism*
  • Folic Acid / pharmacology*
  • Folic Acid Antagonists / pharmacology*
  • Humans
  • Multiple Sclerosis / metabolism
  • Rats
  • Rats, Inbred Lew

Substances

  • Folate Receptor 2
  • Folic Acid Antagonists
  • Folic Acid
  • Aminopterin